Health Economic Evaluations in Inflammatory Bowel Disease in Brazil: A Systematic Review

Abstract

Cost Effectiveness Ratios (ICERs) was -48,469 USD per QALY gained. ConClusions: Study results showed that due to difference between Infliximab and Adalimumab medications` prices, Adalimumab is the dominant alternative in Islamic Republic of Iran, considering its threshold which is about 3,700 USD. Hence it is recommended that Adalimumab to be administered as the first choice of biologic therapy which is controversial to current approach of /most Iranian gastroenterologists.